NCT06927999Phase 2Recruiting

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Study sponsor: ARS Pharmaceuticals, Inc. · SPRY

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants42Estimated
Source updated2026-09-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive. After: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch.

Check registry source

· 1 field changed

Primary completion date changed

Before: Jun 2026. After: Jun 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview